A Study of rhuMAb IFNalpha in Adults With Systemic Lupus Erythematosus

NCT00541749 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG: rhuMAb IFNalpha

Sponsor

Genentech, Inc.